Protagonist Therapeutics, Inc. Selling, General & Administrative Expenses (SG&A)
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General & Administrative Expenses (SG&A) | $1,860.0K | $2,963.0K | $6,961.0K | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M |
Protagonist Therapeutics, Inc. (PTGX) Selling, General & Administrative Expenses (SG&A) comparison analysis
General
LTM Selling, General & Administrative Expenses (SG&A)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
PTGX key stats
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 20.1 0.0% | 30.9 54.1% | 0.2 (99.3%) | 28.6 12,293.1% | 27.4 (4.4%) | 26.6 (2.8%) | 60.0 125.7% | 434.4 624.1% |
| Cost of Goods Sold (COGS) | 0.0 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8 | 1.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.2) 0.0% | (0.3) 0.0% | 20.1 100.0% | 30.9 100.0% | 0.2 100.0% | 28.6 100.0% | 24.6 89.9% | 25.5 96.1% | 60.0 100.0% | 434.4 100.0% |
| Operating Expenses | 9.3 | 14.8 | 32.7 | 58.0 | 73.2 | 80.8 | 93.1 | 153.2 | 158.0 | 153.7 | 181.6 |
| Research & Development Expenses (R&D) | 7.5 | 11.8 | 25.7 | 46.2 | 59.5 | 65.0 | 74.5 | 126.0 | 126.2 | 120.2 | 138.1 |
| Selling, General & Administrative Expenses (SG&A) | 1.9 | 3.0 | 7.0 | 11.8 | 13.7 | 15.7 | 18.6 | 27.2 | 31.7 | 33.5 | 43.5 |
% margin | (9.3) 0.0% | (14.8) 0.0% | (32.7) 0.0% | (37.9) (188.9%) | (42.3) (136.7%) | (80.5) (34,857.6%) | (64.5) (225.4%) | (125.8) (460.0%) | (131.4) (494.2%) | (93.7) (156.1%) | 252.8 58.2% |
| Interest Income | 0.0 | 0.0 | 0.2 | 0.9 | 2.6 | 2.8 | 0.9 | 0.4 | 4.1 | 14.9 | 26.3 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (11.1) | (14.9) | (37.2) | (37.0) | (39.7) | (77.9) | (64.8) | (125.6) | (127.4) | (79.0) | 279.4 |
% effective tax rate | 1.8 (15.8%) | 0.1 (0.4%) | 4.2 (11.2%) | (0.4) 1.1% | (0.8) 2.0% | (0.7) 0.9% | 1.3 (2.0%) | (2.9) 2.3% | (4.0) 3.1% | 0.0 0.0% | 4.2 1.5% |
% margin | (11.1) 0.0% | (14.9) 0.0% | (37.2) 0.0% | (37.0) (184.2%) | (38.9) (125.9%) | (77.2) (33,414.3%) | (66.2) (231.1%) | (122.6) (448.2%) | (123.4) (464.3%) | (79.0) (131.6%) | 275.2 63.3% |
| EPS | (1.88) | (2.52) | (5.72) | (2.09) | (1.74) | (2.98) | (1.92) | (2.65) | (2.52) | (1.39) | 4.47 |
| Diluted EPS | (1.88) | (2.52) | (5.72) | (2.09) | (1.74) | (2.98) | (1.92) | (2.65) | (2.52) | (1.39) | 4.23 |
% margin | (9.1) 0.0% | (14.5) 0.0% | (32.3) 0.0% | (36.6) (182.2%) | (39.2) (126.7%) | (78.3) (33,898.7%) | (63.7) (222.4%) | (123.1) (449.9%) | (131.4) (494.2%) | (90.3) (150.6%) | 252.8 58.2% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Protagonist Therapeutics, Inc.'s Selling, General & Administrative Expenses (SG&A)?
As of today, Protagonist Therapeutics, Inc.'s last 12-month Selling, General & Administrative Expenses (SG&A) is $41.8M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Protagonist Therapeutics, Inc.'s Selling, General & Administrative Expenses (SG&A) growth rate?
Over the last year, Protagonist Therapeutics, Inc.'s Selling, General & Administrative Expenses (SG&A) growth was 24.7%. The average annual Selling, General & Administrative Expenses (SG&A) growth rates for Protagonist Therapeutics, Inc. have been 22.8% over the past three years, 21.5% over the past five years.
3) Is Protagonist Therapeutics, Inc.'s Selling, General & Administrative Expenses (SG&A) growth rate Good?
Over the last year, Protagonist Therapeutics, Inc.'s Selling, General & Administrative Expenses (SG&A) growth was 24.7%, which is higher than industry growth of 0.0%. It indicates that Protagonist Therapeutics, Inc.'s Selling, General & Administrative Expenses (SG&A) growth is Bad.